Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approvedLYNPARZA, jointly developed by AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK), as a maintenance treatment after first-line chemotherapy in patients with BRCA-mutated (BRCAm) ovarian cancer.
LYNPARZA is the only PARP inhibitor approved in Japan.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.